

USSN 10/602,414 Filed June 23, 2003
Docket No. PC25218A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
Application Number				10/602,414	
Filing Date				June 23, 2003	
First Named Inventor				David James Dooley, et al.	
Art Unit				1614	
Examiner Name				Unknown	
Attorney Docket Number				PC25218A	
Sheet	2	of	3		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^o
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
CU		WO 00/15611	03-23-2000	Justin S. Bryans, et al.		
SW		WO 01/28978	04-26-2001	Justin S. Bryans, et al.		

Examiner Signature	S. Wang	Date Considered	9/15/08
-----------------------	---------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/602,414		
		Filing Date	June 23, 2003		
		First Named Inventor	David James Dooley, et al.		
		Art Unit	1614		
Examiner Name	Unknown				
Sheet	3	of	3	Attorney Docket Number	PC25218A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SW		D. J. DOOLEY, et al., "Stimulus-Dependent Modulation of [3H]Norepinephrine Release from Rat Neocortical Slices by Gabapentin and Pregabalin", The Journal of Pharmacology and Experimental Therapeutics, 2000, pp 1086-1093, Vol. 295, No. 3	
		K. FINK, et al., "Inhibition of Neuronal Ca ²⁺ influx by Gabapentin and Pregabalin in the Human Neocortex", Neuro Pharmacology, 2002, pp 229-236, Vol. 42	
		V. HAMRIN, et al., "Gabapentin and Methylphenidate Treatment of a Preadolescent with Attention Deficity Hyperactivity Disorder and Bipolar Disorder", Journal of Child and Adolescent Psychopharmacology, 2002, pp 301-309, Vol. 11, No. 3	
		H. V. KASATOKOVA, et al., "Research of Catecholamine Metabolism Peculiarities of the Children with Attention Deficit Hyperactivity Disorder", Database Biosis Online, Database Accession No. PREV200100125251 ABSTRACT ONLY	
SW		R. RYBACK, et al., "Gabapentin for Behavioral Dyscontrol", American Journal of Psychiatry September 1995, pp 1399, Vol. 152, No. 9	

Examiner Signature		Date Considered	9/15/08
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.